High efficacy has no single definition, and a large toolbox means little when formularies limit access. The panel describes ...
Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data ...
Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.
Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.
In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated ...
Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the ...
Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 ...
Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without ...
The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results